BR112017020058A2 - processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células. - Google Patents

processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células.

Info

Publication number
BR112017020058A2
BR112017020058A2 BR112017020058A BR112017020058A BR112017020058A2 BR 112017020058 A2 BR112017020058 A2 BR 112017020058A2 BR 112017020058 A BR112017020058 A BR 112017020058A BR 112017020058 A BR112017020058 A BR 112017020058A BR 112017020058 A2 BR112017020058 A2 BR 112017020058A2
Authority
BR
Brazil
Prior art keywords
cell
specific
bank
producing
treatment
Prior art date
Application number
BR112017020058A
Other languages
English (en)
Inventor
Bollard Catherine
Cruz Conrad
Hanley Patrick
Original Assignee
Childrens Nat Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Nat Medical Ct filed Critical Childrens Nat Medical Ct
Publication of BR112017020058A2 publication Critical patent/BR112017020058A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

métodos seguros, rápidos e eficientes para produzir células-t específicas para vírus ou específicas para outros antígenos a partir de sangue do cordão umbilical ou de outras amostras contendo células imunes virgens.
BR112017020058A 2015-03-20 2016-03-21 processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células. BR112017020058A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135851P 2015-03-20 2015-03-20
US201562135888P 2015-03-20 2015-03-20
PCT/US2016/023413 WO2016154112A1 (en) 2015-03-20 2016-03-21 Generating virus or other antigen-specific t cells from a naive t cell population

Publications (1)

Publication Number Publication Date
BR112017020058A2 true BR112017020058A2 (pt) 2018-06-05

Family

ID=56977701

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020058A BR112017020058A2 (pt) 2015-03-20 2016-03-21 processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células.

Country Status (9)

Country Link
US (2) US20180072990A1 (pt)
EP (1) EP3271455A4 (pt)
JP (3) JP7362249B2 (pt)
CN (1) CN107429229A (pt)
AU (2) AU2016235388B2 (pt)
BR (1) BR112017020058A2 (pt)
CA (1) CA2980039A1 (pt)
IL (2) IL294055A (pt)
WO (1) WO2016154112A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
WO2017075571A1 (en) 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific cells from a naive t cell population
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
EP3796923A4 (en) * 2018-05-18 2022-03-09 Children's National Medical Center IMPROVED TARGETED T-CELL THERAPY
WO2019222762A1 (en) * 2018-05-18 2019-11-21 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
WO2020032780A1 (ko) * 2018-08-10 2020-02-13 주식회사 유틸렉스 암항원 특이적 세포독성 t세포
JP2023537161A (ja) * 2020-08-14 2023-08-30 シャンハイ・シンフア・バイオ・ファーマスーティカル・サイエンス・アンド・テクノロジー・カンパニー・リミテッド ユニバーサル免疫細胞の製造方法及びその応用
US20220257651A1 (en) 2020-12-23 2022-08-18 Mana Therapeutics Methods and delivery of allogeneic cell products

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003634B1 (ru) * 1998-10-05 2003-08-28 Фармэкса А/С Новые способы терапевтической вакцинации
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2005070959A2 (en) * 2004-01-23 2005-08-04 Vievax Corp. Compositions comprising immune response altering agents and methods of use
RU2478400C2 (ru) * 2006-12-27 2013-04-10 Эмори Юниверсити Композиции и способы лечения инфекций и опухолей
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
JP5717116B2 (ja) * 2008-12-22 2015-05-13 学校法人昭和大学 抗原特異的ヒトＴｈ１７細胞を調整する方法
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US20130115617A1 (en) * 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US9114100B2 (en) * 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
NZ723731A (en) * 2011-04-08 2020-05-29 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US10351824B2 (en) 2011-12-12 2019-07-16 Cell Medica Limited Process of expanding T cells
KR102247979B1 (ko) * 2012-05-25 2021-05-04 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
ES2886999T3 (es) * 2013-03-27 2021-12-21 Immunovaccine Technologies Inc Procedimiento para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
WO2015066057A2 (en) * 2013-10-28 2015-05-07 Baylor College Of Medicine Expansion of cmv-specific t cells from cmv-seronegative donors
CN103966163B (zh) * 2014-04-08 2016-07-06 安德生细胞生物（湖北）有限公司 增强型dcik细胞制备方法及其细胞制剂
WO2015191874A1 (en) * 2014-06-12 2015-12-17 Children's National Medical Center Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US10414810B2 (en) * 2015-05-07 2019-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Double mutant survivin vaccine
EP4212547A1 (en) * 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
CN117018170A (zh) * 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
WO2018005712A1 (en) * 2016-06-28 2018-01-04 Geneius Biotechnology, Inc. T cell compositions for immunotherapy
WO2018055191A1 (en) * 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
MA47678A (fr) * 2017-03-03 2021-05-26 Treos Bio Ltd Plateforme personnalisée d'identification de peptide immunogène
EP3796923A4 (en) * 2018-05-18 2022-03-09 Children's National Medical Center IMPROVED TARGETED T-CELL THERAPY

Also Published As

Publication number Publication date
WO2016154112A1 (en) 2016-09-29
AU2022201045A1 (en) 2022-03-10
US20180072990A1 (en) 2018-03-15
IL254565B (en) 2022-07-01
CN107429229A (zh) 2017-12-01
CA2980039A1 (en) 2016-09-29
IL254565A0 (en) 2017-11-30
IL294055A (en) 2022-08-01
US20210277355A1 (en) 2021-09-09
JP7362249B2 (ja) 2023-10-17
AU2016235388A1 (en) 2017-09-21
JP2023130355A (ja) 2023-09-20
AU2016235388B2 (en) 2022-02-03
JP2018509938A (ja) 2018-04-12
EP3271455A1 (en) 2018-01-24
JP2021181444A (ja) 2021-11-25
EP3271455A4 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
BR112017020058A2 (pt) processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células.
IL251261B (en) Reagents and methods for the identification, enrichment and/or expansion of antigen-specific T-cells
SG11201608862SA (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
BR112017013385A2 (pt) anticorpos para tigit
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
EP3234602A4 (en) Methods for identifying multiple epitopes in selected sub-populations of cells
MY189338A (en) Method for treating cancer
MA39819A (fr) Méthodes et compositions d'immunomodulation
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
EP3305888A4 (en) Cell treatment method, laser processing machine, and cell culture vessel
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
BR112017003620A2 (pt) métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
MA45488A (fr) Procédés, kits et appareil de culture de cellules
BR112016016937A8 (pt) partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t
EP3181681A4 (en) Medical device, method for culturing cells, fluorine-containing cyclic olefin polymer, fluorine-containing cyclic olefin polymer composition, and cultured cells
MX2016010100A (es) Secuenciacion libre de error de acido desoxirribonucleico (adn).
EP3150704A4 (en) Culture method and cell mass
EP3224349A4 (en) Method for culturing natural killer cells using t cells
SG11201701562WA (en) Cell trapping method, method for producing specific cell-trapping device, and method for producing specific cell-containing solution
EP3463399A4 (en) METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENIC T CELLS
EP3166647A4 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
EP3261049A4 (en) Soc management system of energy storage device, and method therefor
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.